NanoRepro AG - Asset Resilience Ratio
NanoRepro AG (NN6) has an Asset Resilience Ratio of 19.19% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how NanoRepro AG's Asset Resilience Ratio has changed over time. Check NanoRepro AG (NN6) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down NanoRepro AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NanoRepro AG (NN6) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €7.29 Million | 19.19% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €7.29 Million | 19.19% |
Asset Resilience Insights
- Good Liquidity Position: NanoRepro AG maintains a healthy 19.19% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
NanoRepro AG Industry Peers by Asset Resilience Ratio
Compare NanoRepro AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ICON Public Limited Company
F:IJF |
Diagnostics & Research | 0.00% |
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 32.97% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
Annual Asset Resilience Ratio for NanoRepro AG (2010–2024)
The table below shows the annual Asset Resilience Ratio data for NanoRepro AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 23.31% | €9.10 Million ≈ $10.64 Million |
€39.03 Million ≈ $45.62 Million |
-26.43pp |
| 2023-12-31 | 49.74% | €20.62 Million ≈ $24.11 Million |
€41.46 Million ≈ $48.47 Million |
-13.44pp |
| 2022-12-31 | 63.18% | €31.26 Million ≈ $36.55 Million |
€49.48 Million ≈ $57.84 Million |
+27.78pp |
| 2021-12-31 | 35.40% | €28.02 Million ≈ $32.76 Million |
€79.15 Million ≈ $92.53 Million |
+24.98pp |
| 2020-12-31 | 10.42% | €1.16 Million ≈ $1.36 Million |
€11.17 Million ≈ $13.06 Million |
-4.93pp |
| 2019-12-31 | 15.35% | €737.15K ≈ $861.81K |
€4.80 Million ≈ $5.62 Million |
-15.13pp |
| 2018-12-31 | 30.48% | €1.77 Million ≈ $2.07 Million |
€5.81 Million ≈ $6.79 Million |
+17.90pp |
| 2017-12-31 | 12.58% | €528.05K ≈ $617.35K |
€4.20 Million ≈ $4.91 Million |
-2.51pp |
| 2016-12-31 | 15.09% | €530.12K ≈ $619.77K |
€3.51 Million ≈ $4.11 Million |
+14.98pp |
| 2010-12-31 | 0.11% | €2.15K ≈ $2.52K |
€1.94 Million ≈ $2.27 Million |
-- |
About NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more